Top 10 iomcworld.org Competitors

sbah.org.za

the steve biko academic hospital is a purely tertiary healthcare institution, rendering specialized and highly specialized services to medically referred patients.

nucleodoconhecimento.com.br

Torne-se editor da Revista Núcleo do Conhecimento e potencialize sua Carreira Acadêmica! Ser editor na Revista Científica Multidisciplinar Núcleo do Conhecimento é uma oportunidade única para quem deseja se destacar no mundo acadêmico e impulsionar sua carreira com reconhecimento e autoridade. Nossa revista é uma plataforma prestigiada, de alto impacto, indexada e com ampla visibilidade […]

hkmj.org

Hong Kong Medical Journal Clinical Epidemiology Workshop series Workshop 1—Dissection of a medical journal paper Workshop 2—General approach to critical appraisal of a medical journal paper Workshop 3—Source of bias in case series, patient cohorts, and randomised controlled trials Workshop 4—Sources of bias in case-referent studies Workshop 5—Sources of bias in cohort studies Workshop 6—Sources of bias in cross-sectional studies; summary on sources of bias for different study designs Workshop 7—Appraising a study on diagnosis Workshop 8—Appraising a study on therapy Workshop 9—Appraisi

rbcp.org.br

a revista brasileira de cirurgia plástica é o órgão oficial de divulgação da sociedade brasileira de cirurgia plástica (sbcp), tem como objetivo registrar a produção científica em cirurgia plástica, fomentar o estudo, aperfeiçoamento e atualização dos profissionais da especialidade.

sosyalarastirmalar.com

the journal of international social research

rmdopen.bmj.com

Objective Glucocorticoid (GC) tapering and withdrawal to reduce damage represents a key aspect of the European Alliance of Associations for Rheumatology (EULAR) SLE recommendations. However, optimal strategies for relapse-free GC cessation remain ill-defined. We characterised clinical predictors and their combined effect on flares in patients with SLE who discontinued GC.Methods Retrospective cohort of 324 patients with active SLE (PGA ≥1.5 and/or SLEDAI-2K ≥6) who received GC as part of treatment intensification (median follow-up 60 months). Survival and generalised linear models estimated SELENA-SLEDAI flare risks and their predictors.Results GCs were discontinued in 220 (67.9%) patients with 1-year risks for overall and severe flares of 50% and 25%, respectively (HR: 1.48; 95% CI: 1.12 to 1.96 for overall flares; HR: 1.52; 95% CI: 1.03 to 2.25 for severe flares, compared with non-withdrawers). Flare risk was lowered when GCs were ceased during remission (DORIS) or Lupus Low Disease Activity State (LLDAS; excluding remission) (HR for severe flares: 0.23; 0.12 to 0.43 and 0.30; 0.18 to 0.50, respectively), with each additional month in targets providing further protection. Hydroxychloroquine prevented total (HR: 0.37; 0.26 to 0.53) and severe flares (HR: 0.33; 0.21 to 0.52), while mycophenolate and azathioprine reduced overall flares. Prednisone tapering from 7.5 mg/day to 0 over >6 months improved severe flare-free outcome (HR: 0.57; 0.37 to 0.90). Random survival forests identified DORIS/LLDAS, hydroxychloroquine use and slow GC tapering as top predictors, whose coexistence reduced overall and severe flares by ~25 fold and ~50 fold, respectively. This combination reduced damage (IRR: 0.31; 0.08 to 0.84) without inducing flares (IRR: 0.52; 95% CI: 0.18 to 1.16) compared with GC non-withdrawers.Conclusion Low or absent disease activity, slow tapering and hydroxychloroquine use minimise the risk of flares, facilitating GC discontinuation—a major goal in SLE.

ww3.rics.org

In her latest column, RICS President Ann Gray discusses inspirational stories from our profession, this year’s MIPIM in Cannes and Whole Life Carbon Assessment

liuc.academia.edu

Università Carlo Cattaneo - LIUC on academia.edu

otp.healthcarefinancedirect.com

healthcare finance direct - customer portal